Research output: Contribution to journal › Article › peer-review
Minimum inhibitory concentrations of aztreonam–avibactam, ceftazidime–avibactam and meropenem in clinical isolates of Klebsiella pneumoniae harboring carbapenemase genes. / Ageevets, V.; Sulian, O.; Avdeeva, A.; Chulkova, P.; Ageevets, I.; Gostev, V.; Alieva, K.; Golikova, M.; Sidorenko, S.
In: Journal of Antibiotics, Vol. 77, No. 10, 01.07.2024, p. 706-710.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Minimum inhibitory concentrations of aztreonam–avibactam, ceftazidime–avibactam and meropenem in clinical isolates of Klebsiella pneumoniae harboring carbapenemase genes
AU - Ageevets, V.
AU - Sulian, O.
AU - Avdeeva, A.
AU - Chulkova, P.
AU - Ageevets, I.
AU - Gostev, V.
AU - Alieva, K.
AU - Golikova, M.
AU - Sidorenko, S.
N1 - Export Date: 19 October 2024 CODEN: JANTA Адрес для корреспонденции: Ageevets, V.; Pediatric Research and Clinical Center for Infectious DiseasesRussian Federation; эл. почта: ageevets@list.ru Химические вещества/CAS: avibactam plus ceftazidime, 1393723-27-7; meropenem, 96036-03-2; serine, 56-45-1, 6898-95-9; avibactam, 1192500-31-4, 1192491-61-4; aztreonam, 78110-38-0; beta lactamase, 9073-60-3; ceftazidime, 72558-82-8, 73547-61-2, 78439-06-2; Anti-Bacterial Agents; avibactam; avibactam, ceftazidime drug combination; Azabicyclo Compounds; Aztreonam; Bacterial Proteins; beta-Lactamases; carbapenemase; Ceftazidime; Drug Combinations; Meropenem Производители: Sigma Aldrich, United States Сведения о финансировании: Russian Science Foundation, RSF, 21-74-10090 Сведения о финансировании: Russian Science Foundation, RSF Текст о финансировании 1: This research was funded by the Russian Science Foundation, grant number 21-74-10090.
PY - 2024/7/1
Y1 - 2024/7/1
N2 - This study was aimed at understanding the distributions of the MICs (minimum inhibitory concentrations) of aztreonam–avibactam, ceftazidime–avibactam and meropenem with respect to Klebsiella pneumoniae isolates producing different types of carbapenemases and their combinations. K. pneumoniae isolates were collected between 2019 and 2022 from 37 hospitals. PCR was used to screen for blaKPC-, blaNDM- and blaOXA-48-like genes. MICs were determined by the broth microdilution method for meropenem, aztreonam–avibactam and ceftazidime–avibactam at a constant avibactam concentration of 4 mg l−1. MIC distributions were analyzed for groups of isolates based on the identified carbapenemases including their combinations. The AZT/AVI MIC50 and MIC90 for all NDM-positive isolates were 0.25 and 0.5, respectively, and for serine-carbapenemase-only producers, they were 0.25 and 1 mg l−1, respectively. The CZD/AVI MIC50 and MIC90 values for serine-carbapenemase-only producers were 1 and 4 mg l−1, respectively. The AZT/AVI MIC50 and MIC90 values for co-producers and single carbapenemase producers were the same (i.e., 0.25 and 1 mg l−1, respectively). The total proportion of meropenem-susceptible isolates (≤8 mg l−1) among all the carbapenemase producers was 25.1% (31.1% among single-carbapenemase producers and 9.2% among co-producers). The results support the use of aztreonam–avibactam for the empirical treatment of infections caused by any carbapenemase producers. © The Author(s), under exclusive licence to the Japan Antibiotics Research Association 2024.
AB - This study was aimed at understanding the distributions of the MICs (minimum inhibitory concentrations) of aztreonam–avibactam, ceftazidime–avibactam and meropenem with respect to Klebsiella pneumoniae isolates producing different types of carbapenemases and their combinations. K. pneumoniae isolates were collected between 2019 and 2022 from 37 hospitals. PCR was used to screen for blaKPC-, blaNDM- and blaOXA-48-like genes. MICs were determined by the broth microdilution method for meropenem, aztreonam–avibactam and ceftazidime–avibactam at a constant avibactam concentration of 4 mg l−1. MIC distributions were analyzed for groups of isolates based on the identified carbapenemases including their combinations. The AZT/AVI MIC50 and MIC90 for all NDM-positive isolates were 0.25 and 0.5, respectively, and for serine-carbapenemase-only producers, they were 0.25 and 1 mg l−1, respectively. The CZD/AVI MIC50 and MIC90 values for serine-carbapenemase-only producers were 1 and 4 mg l−1, respectively. The AZT/AVI MIC50 and MIC90 values for co-producers and single carbapenemase producers were the same (i.e., 0.25 and 1 mg l−1, respectively). The total proportion of meropenem-susceptible isolates (≤8 mg l−1) among all the carbapenemase producers was 25.1% (31.1% among single-carbapenemase producers and 9.2% among co-producers). The results support the use of aztreonam–avibactam for the empirical treatment of infections caused by any carbapenemase producers. © The Author(s), under exclusive licence to the Japan Antibiotics Research Association 2024.
KW - avibactam plus aztreonam
KW - avibactam plus ceftazidime
KW - carbapenemase
KW - meropenem
KW - serine
KW - antiinfective agent
KW - avibactam
KW - avibactam, ceftazidime drug combination
KW - azabicyclo derivative
KW - aztreonam
KW - bacterial protein
KW - beta lactamase
KW - ceftazidime
KW - antibiotic sensitivity
KW - Article
KW - bacterium isolate
KW - broth dilution
KW - controlled study
KW - Japan
KW - Klebsiella pneumoniae
KW - MIC50
KW - MIC90
KW - minimum inhibitory concentration
KW - nonhuman
KW - drug combination
KW - drug effect
KW - drug therapy
KW - genetics
KW - human
KW - Klebsiella infection
KW - metabolism
KW - microbial sensitivity test
KW - microbiology
KW - Anti-Bacterial Agents
KW - Azabicyclo Compounds
KW - Aztreonam
KW - Bacterial Proteins
KW - beta-Lactamases
KW - Ceftazidime
KW - Drug Combinations
KW - Humans
KW - Klebsiella Infections
KW - Meropenem
KW - Microbial Sensitivity Tests
UR - https://www.mendeley.com/catalogue/5b9c9697-78b0-3715-a044-113295979334/
U2 - 10.1038/s41429-024-00758-8
DO - 10.1038/s41429-024-00758-8
M3 - статья
VL - 77
SP - 706
EP - 710
JO - Journal of Antibiotics
JF - Journal of Antibiotics
SN - 0021-8820
IS - 10
ER -
ID: 126385550